Indications And Dose
HIV infection (initiated by a specialist) ▶BY MOUTH ▶Adult: 1 tablet once daily
PDF page 717
Loading InternPractice…
Drug reference
HIV infection (initiated by a specialist) ▶BY MOUTH ▶Adult: 1 tablet once daily
PDF page 717
Scottish Medicines Consortium (SMC) decisions SMC No. 1290/18 The Scottish Medicines Consortium has advised (January 2018) that darunavir with cobicistat, emtricitabine and tenofovir alafenamide (Symtuza ®) is accepted for use within NHS Scotland for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults Infection and adolescents (aged 12 years and older with body weight at least 40 kg). All Wales Medicines Strategy Group (AWMSG) decisions AWMSG No. 2418 The All Wales Medicines Strategy Group has advised (March 2018) that darunavir with cobicistat, emtricitabine and tenofovir alafenamide (Symtuza ®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).
PDF page 717
MHRA/CHM ADVICE: DARUNAVIR BOOSTED WITH COBICISTAT: AVOID USE IN PREGNANCY DUE TO RISK OF TREATMENT FAILURE AND MATERNAL-TO-CHILD TRANSMISSION OF HIV-1 (JULY 2018) Pharmacokinetic data show mean exposure of darunavir boosted with cobicistat (available in combination in Rezolsta ® and Symtuza ®) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child. For further information, see Pregnancy.
PDF page 717
→Appendix 1: cobicistat. HIV-protease inhibitors. tenofovir alafenamide
PDF page 717
Manufacturer advises not to be initiated during pregnancy due to low darunavir exposure; women who become pregnant during therapy should be switched to an alternative regimen.
PDF page 717
Manufacturer advises avoid if eGFR less than 30 mL/minute/1.73 m2—no information available.
PDF page 717
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Symtuza (Janssen-Cilag Ltd) A Tenofovir alafenamide (as Tenofovir alafenamide fumarate) 10 mg, Cobicistat 150 mg, Emtricitabine 200 mg, Darunavir (as Darunavir ethanolate) 800 mg Symtuza 800mg/150mg/200mg/10mg tablets | 30 tablet P £672.97 eiiii F 693
PDF page 717
Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.
PDF page 717
1 tablet once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 717